<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03362164</url>
  </required_header>
  <id_info>
    <org_study_id>FAZiT-2001</org_study_id>
    <nct_id>NCT03362164</nct_id>
  </id_info>
  <brief_title>Evaluation of HEArt invoLvement in Patients With FABRY Disease</brief_title>
  <acronym>HEAL-FABRY</acronym>
  <official_title>Prospective Monocentric Cohort Study to Evaluate Predictors for Heart Failure and Sudden Cardiac Death in Patients With Fabry Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuerzburg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Competence Network Heart Failure</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St George's, University of London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuerzburg University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates predictors for the incidence of arrhythmias and sudden cardiac death as
      well as terminal heart failure in patients with Fabry disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fabry disease is a rare disease and part of the group of lysosomal storage disorders. Natural
      history of Fabry disease has proven poor survival to ages &gt;50 years outlining the importance
      to evaluate cardiac symptoms and outcomes of patients with Fabry disease.

      This study is a prospective cohort study and observes patients since 2001. Through this
      long-term experience and the relative high number of patients this study is suggested to help
      estimating the risk of cardiac arrhythmias and sudden cardiac death (SCD) as well as death or
      heart transplantation due to terminal heart failure.

      All patients in treatment in the Fabry Center Wuerzburg (FAZiT) are included in this study if
      informed consent is provided.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2001</start_date>
  <completion_date type="Anticipated">March 2032</completion_date>
  <primary_completion_date type="Anticipated">March 2032</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>From date of inclusion until the date of first documented event, up to the year 2032</time_frame>
    <description>Patients sustaining cardiac death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart transplantation</measure>
    <time_frame>From date of inclusion until the date of first documented event, up to the year 2032</time_frame>
    <description>On the basis of severe cardiac damage heart transplantation is needed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malign Arrhythmias</measure>
    <time_frame>From date of inclusion until the date of death, up to the year 2032</time_frame>
    <description>Patients suffering any malign arrhythmias</description>
  </secondary_outcome>
  <enrollment type="Anticipated">650</enrollment>
  <condition>Rare Diseases</condition>
  <condition>Fabry Disease</condition>
  <condition>Fabry Disease, Cardiac Variant</condition>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      ECG, Holter ECG, Echo, Cardiac MRI, Endomyocardial Biopsy, Kidney Biopsy, Cranial MRI, Skin
      Biopsy, EDTA Blood, Serum, Plasma, Urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes every patient with Fabry disease who is seen in the FAZiT
        Wuerzburg. No limitations are made.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fabry disease (genetically confirmed)

          -  Signed informed consent

          -  18 years and older

        Exclusion Criteria:

          -  No informed consent

          -  Withdrawal of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Peter Nordbeck, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuerzburg University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Nordbeck, MD, PhD</last_name>
    <phone>004993120139181</phone>
    <email>nordbeck_p@ukw.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonas Muentze, MD</last_name>
    <phone>004993120139958</phone>
    <email>muentze_j@ukw.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wuerzburg University Hospital</name>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina Turkin</last_name>
      <phone>004993120139714</phone>
      <email>turkin_i@ukw.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Oder D, Üçeyler N, Liu D, Hu K, Petritsch B, Sommer C, Ertl G, Wanner C, Nordbeck P. Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y. BMJ Open. 2016 Apr 8;6(4):e010422. doi: 10.1136/bmjopen-2015-010422.</citation>
    <PMID>27059467</PMID>
  </results_reference>
  <results_reference>
    <citation>Seydelmann N, Liu D, Krämer J, Drechsler C, Hu K, Nordbeck P, Schneider A, Störk S, Bijnens B, Ertl G, Wanner C, Weidemann F. High-Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease. J Am Heart Assoc. 2016 May 31;5(6). pii: e002839. doi: 10.1161/JAHA.115.002839. Erratum in: J Am Heart Assoc. 2016;5(9). pii: e002114. doi: 10.1161/JAHA.116.002114.</citation>
    <PMID>27247331</PMID>
  </results_reference>
  <results_reference>
    <citation>Weidemann F, Maier SK, Störk S, Brunner T, Liu D, Hu K, Seydelmann N, Schneider A, Becher J, Canan-Kühl S, Blaschke D, Bijnens B, Ertl G, Wanner C, Nordbeck P. Usefulness of an Implantable Loop Recorder to Detect Clinically Relevant Arrhythmias in Patients With Advanced Fabry Cardiomyopathy. Am J Cardiol. 2016 Jul 15;118(2):264-74. doi: 10.1016/j.amjcard.2016.04.033. Epub 2016 May 5.</citation>
    <PMID>27265676</PMID>
  </results_reference>
  <results_reference>
    <citation>Lenders M, Oder D, Nowak A, Canaan-Kühl S, Arash-Kaps L, Drechsler C, Schmitz B, Nordbeck P, Hennermann JB, Kampmann C, Reuter S, Brand SM, Wanner C, Brand E. Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease. J Intern Med. 2017 Sep;282(3):241-253. doi: 10.1111/joim.12647. Epub 2017 Jul 26.</citation>
    <PMID>28682471</PMID>
  </results_reference>
  <results_reference>
    <citation>Oder D, Liu D, Hu K, Üçeyler N, Salinger T, Müntze J, Lorenz K, Kandolf R, Gröne HJ, Sommer C, Ertl G, Wanner C, Nordbeck P. α-Galactosidase A Genotype N215S Induces a Specific Cardiac Variant of Fabry Disease. Circ Cardiovasc Genet. 2017 Oct;10(5). pii: e001691. doi: 10.1161/CIRCGENETICS.116.001691.</citation>
    <PMID>29018006</PMID>
  </results_reference>
  <results_reference>
    <citation>Köping M, Shehata-Dieler W, Cebulla M, Rak K, Oder D, Müntze J, Nordbeck P, Wanner C, Hagen R, Schraven S. Cardiac and renal dysfunction is associated with progressive hearing loss in patients with Fabry disease. PLoS One. 2017 Nov 21;12(11):e0188103. doi: 10.1371/journal.pone.0188103. eCollection 2017.</citation>
    <PMID>29161295</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2017</study_first_submitted>
  <study_first_submitted_qc>November 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2017</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuerzburg University Hospital</investigator_affiliation>
    <investigator_full_name>PD Dr. Peter Nordbeck</investigator_full_name>
    <investigator_title>Head Consultant Cardiology and Chief of Electrophysiology</investigator_title>
  </responsible_party>
  <keyword>Fabry</keyword>
  <keyword>Fibrosis</keyword>
  <keyword>Dialysis</keyword>
  <keyword>Stroke</keyword>
  <keyword>Chronic kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Rare Diseases</mesh_term>
    <mesh_term>Fabry Disease</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

